The overall objective of this proposal is to understand the mechanism by which a-defensin-1 inhibits HIV-1 replication. Alpha-defensins are cationic, cysteine (Cys)-rich peptides and play an important role in innate host defense. Recent studies including ours clearly demonstrate that alpha-defensin-1 has anti-HIV-1 activity. Our recent finding demonstrates that adefensin- 1 acts on the virion and the cell, although the direct effect on virions occurs under restricted conditions. We have shown that alpha-defensin-1 at a non-cytotoxic, physiological concentration can inhibit HIV-1 replication following viral entry, suggesting that alpha-defensin-1 has an effect(s) on the target cells where HIV-1 replicates. In primary CD4+ T cells, we have identified that alpha-defensin-1 inhibits protein Kinase C (PKC) signaling, a pathway important for HIV-1 infection and immune cell function. Our hypothesis is that alpha-defensin-1 has significant anti-HIV-1 activity and this activity is largely mediated through cell signaling in target cells. This proposal will study the mechanism(s) of action in primary CD4+ T cells and macrophages, the major target cells for HIV-1.
In Aim 1, we will extend the post-entry study by evaluating the antiviral activity of alpha-defensin-1 against HIV-1 primary isolates. The direct effect on HIV-1 virions will be further studied using R5 viruses. We will identify the point in the virus life cycle blocked by a-defensin-1 in these primary cells.
In Aim 2, we will assess the role of PKC in alpha-defensin- 1-mediated HIV-1 inhibition. Our preliminary results indicate that PKCalpha and (3 are involved in HIV-1 inhibition by alpha-defensin-1. We will assess activities of PKCalpha and (3 in primary CD4+ T cells in response to a-defensin-1. We will also evaluate the interaction of alpha-defensin-1 with PKCalpha or beta. The role of PKCalpha and beta in alpha-defensin-1-mediated anti-HIV activity will be examined by introducing constitutively active PKC.
In Aim 3, we will study the contribution of structure of a-defensin-1 to the anti-HIV-1 activity. We will explore the difference in native compared to recombinant and synthetic alpha-defensin-1 in anti-HIV affect. We will define amino acid residues in a-defensin-1 important for its anti-HIV-1 activity. These studies will offer insights into the function of alpha-defensin-1 in innate immune responses against HIV-1 infection and provide an understanding of the structure-function relationship of a-defensin-1 that is essentially important in view of the efforts to develop defensin-derived peptides for prevention and therapeutic use.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI062430-01A1
Application #
7054394
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Plaeger, Susan F
Project Start
2005-06-01
Project End
2006-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$296,625
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Chang, Theresa L; Teleshova, Natalia; Rapista, Aprille et al. (2007) SAMMA, a mandelic acid condensation polymer, inhibits dendritic cell-mediated HIV transmission. FEBS Lett 581:4596-602